Cargando…

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study

BACKGROUND: Immune checkpoint inhibitors (ICIs) have improved survival and are increasingly used for non-small cell lung cancer. However, use may be limited by immune-related adverse events such as checkpoint-inhibitor pneumonitis (CIP). Literature estimates for CIP incidence are inconsistent. Real-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tiu, Bruce C, Zubiri, Leyre, Iheke, James, Pahalyants, Vartan, Theodosakis, Nicholas, Ugwu-Dike, Pearl, Seo, Jayhyun, Tang, Kimberly, Sise, Meghan E, Sullivan, Ryan, Naidoo, Jarushka, Mooradian, Meghan J, Semenov, Yevgeniy R, Reynolds, Kerry L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204442/ https://www.ncbi.nlm.nih.gov/pubmed/35705313 http://dx.doi.org/10.1136/jitc-2022-004670

Ejemplares similares

Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA
por: Kalinich, Mark, et al.
Publicado: (2021)

Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis
por: Durbin, Sienna M, et al.
Publicado: (2020)

Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Klebanov, Nikolai, et al.
Publicado: (2021)

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
por: Zubiri, Leyre, et al.
Publicado: (2021)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study
por: Lee, Meghan D, et al.
Publicado: (2021)

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
por: Balaji, Aanika, et al.
Publicado: (2021)

Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy
por: Falade, Ayo S., et al.
Publicado: (2022)

28552 Risk of COVID-19 and subsequent mortality among patients receiving immunosuppressive biologic therapy: A retrospective matched cohort study
por: Pahalyants, Vartan, et al.
Publicado: (2021)

28630 Use of systemic immunosuppressive treatment is not related to COVID-19 positivity in a retrospective review of patients in Massachusetts
por: Murphy, William, et al.
Publicado: (2021)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

Immune checkpoint inhibitor-associated celiac disease
por: Badran, Yousef R, et al.
Publicado: (2020)

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023)

27147 Antimalarials as pre-exposure prophylaxis for COVID-19: A retrospective matched cohort study
por: Klebanov, Nikolai, et al.
Publicado: (2021)

Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts
por: Pahalyants, Vartan, et al.
Publicado: (2022)

Reply to: “COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated”
por: Pahalyants, Vartan, et al.
Publicado: (2022)

Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control
por: Hughes, Michael S., et al.
Publicado: (2019)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
por: Beattie, Jason, et al.
Publicado: (2021)

Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis
por: Franken, Amelie, et al.
Publicado: (2022)

Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI
por: Gupta, Shruti, et al.
Publicado: (2022)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
por: Sise, Meghan E, et al.
Publicado: (2023)

Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
por: Zlotoff, Daniel A, et al.
Publicado: (2021)

Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors
por: Drobni, Zsofia D, et al.
Publicado: (2021)

Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study
por: Karayama, Masato, et al.
Publicado: (2023)

Acute kidney injury in patients treated with immune checkpoint inhibitors
por: Gupta, Shruti, et al.
Publicado: (2021)

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
por: Rogiers, Aljosja, et al.
Publicado: (2021)

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
por: Sierra-Rodero, Belén, et al.
Publicado: (2021)

Elicitation of stem-like CD8(+) T cell responses via lymph node-targeted chemoimmunotherapy evokes systemic tumor control
por: Manspeaker, Margaret P, et al.
Publicado: (2022)

Treatment of Pneumonitis: From the Allgemeine Wiener Med. Zeitung
por: Hermann, A.
Publicado: (1874)

Treatment of Pneumonitis: From the Allgemeine Wiener Med. Zeitung
por: Hermann, A.
Publicado: (1874)

Treatment of Pneumonitis: From the Allgemeine Wiener Med. Zeitung
por: Hermann, A.
Publicado: (1874)

Treatment of Pneumonitis: From the Allgemeine Wiener Medical Zeitung
por: Hermann, A.
Publicado: (1874)

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
por: Naidoo, Jarushka, et al.
Publicado: (2021)

Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study
por: Tiu, Bruce C, et al.
Publicado: (2023)

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
por: Yap, Timothy A, et al.
Publicado: (2022)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
por: Bhave, Prachi, et al.
Publicado: (2022)

Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
por: Zubiri, Leyre, et al.
Publicado: (2019)

336 Risks of COVID-19 infection and mortality for patients on biologics
por: Pahalyants, V., et al.
Publicado: (2021)

028 Use of systemic immunosuppressive treatment is not related to COVID-19 infection in a retrospective review of patients in Massachusetts
por: Murphy, W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sipvim7gfvkud3b1vnol6bhj3a